NRTI and NtRTI Combination for HIV Prophylaxis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preventing HIV infection, such as pre-exposure prophylaxis, have limited success, and there is a need for a chemoprophylactic composition and dosing regimen that can effectively block early-stage retroviral infection in hosts before it becomes self-propagating, especially in high-risk populations.
Innovation Solution
Administering a combination of a nucleoside reverse transcriptase inhibitor (NRTI) and a nucleotide reverse transcriptase inhibitor (NtRTI) prior to exposure to HIV, either as a single dose or multiple temporally spaced doses, to prevent the retrovirus from becoming self-replicating in a primate host, with the option of additional doses post-exposure to maintain therapeutic levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pre-exposure prophylaxis with tenofovir is administered at a dose equivalent to that used in humans, then protection against rectal SHIV transmission is achieved, but the protection is only partial and oral daily dosing is required
Solution Approach 1:
The patent combines tenofovir with another antiretroviral agent (emtricitabine or raltegravir) to create a combination prophylactic regimen. This merging of multiple agents aims to enhance protection efficacy while potentially simplifying the dosing requirements compared to tenofovir monotherapy
Solution Approach 2:
The patent modifies the dosing parameters by administering tenofovir at doses higher than those used in human HIV treatment (based on primate SIV challenge models). This parameter change seeks to achieve complete protection rather than partial protection, potentially allowing for less frequent dosing intervals
2Reliability
If HAART therapy is initiated in a pre-exposure prophylactic regimen, then retroviral titer is lowered, but long term toxicity concerns remain and the potential to infect others is retained
Solution Approach 1:
The patent extracts and focuses on the prophylactic application of specific antiretroviral agents (tenofovir combined with emtricitabine or raltegravir) rather than using full HAART regimens. This extraction allows for targeted viral suppression with reduced toxicity and lower transmission risk compared to comprehensive HAART therapy
Solution Approach 2:
The patent employs partial action by using a simplified two-drug prophylactic regimen instead of full HAART. This partial approach provides sufficient viral suppression for prevention purposes while minimizing the harmful effects associated with more aggressive multi-drug therapy
3Ease of operation
If a single dose of NRTI and NtRTI combination is administered prior to exposure, then protection against self-replicating infection is achieved, but the duration of protection is limited
Solution Approach 1:
The patent establishes periodic dosing intervals for the NRTI and NtRTI combination, where subsequent doses are administered at predetermined intervals to maintain protective drug levels. This periodic action balances the simplicity of dosing with the need for sustained protection over extended periods
Solution Approach 2:
The patent ensures continuous protection by maintaining therapeutic drug levels through scheduled repeat dosing. The useful action of viral inhibition is sustained continuously through this regimen, preventing gaps in protection that would occur with single-dose administration
Data Source
AI summary
A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host. A process for controlling retrovirus transmission within a population includes the administration to a subpopulation at high risk for contracting an immunodeficiency retroviral infection the detailed combination prior to sexual exposure to a source of immunodeficiency retrovirus so as to preclude the immunodeficiency retrovirus from becoming self-replicating in a member of the subpopulation.